Literature DB >> 2859432

Cyclosporin and rifampicin in renal transplantation.

R D Allen, A G Hunnisett, P J Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2859432     DOI： 10.1016/s0140-6736(85)91746-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Effect of topical rifamycin SV treatment on cyclosporin A blood levels in a renal transplant recipient.

Authors:  E Renoult; J Hubert; P Trechot; D Hestin; M Kessler; J L'Hermite
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

5.  Cyclosporine trough concentration monitoring in liver transplant patients.

Authors:  G J Burckart; R J Ptachcinski; R Venkataramanan; S Iwatsuki; C Esquivel; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

6.  Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography.

Authors:  G J Burckart; R Venkataramanan; R J Ptachcinski; T E Starzl; B P Griffith; T R Hakala; J T Rosenthal; R L Hardesty; S Iwatsuki; J Brady
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

7.  Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

Authors:  S M Borcherding; T L Bastian; T H Self; N Abou-Shala; B W LeDuc; R L Lalonde
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

9.  Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat.

Authors:  P E Queneau; P Bertault-Peres; M Guitaoui; E Mesdjian; A Durand; J C Montet
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

Review 10.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.